European radiopharmaceutical startups Nuclidium and Actithera have raised substantial venture capital to advance their novel cancer therapies. Nuclidium secured $99 million in Series B financing to develop its platform technology across Basel and Munich. Actithera, despite operating as a one-person company for much of its existence, raised $75.5 million in Series A funding to initiate clinical development of a fibroblast activation protein (FAP) targeting radioligand therapy. These investments underscore growing interest and innovation in radiopharmaceuticals, buoyed by recent success stories such as Novartis’ Pluvicto. The sector continues to attract increasing venture activity, highlighting the potential for more precise tumor-targeting therapies.